In today’s recent session, 0.57 million shares of the AbCellera Biologics Inc (NASDAQ:ABCL) have been traded, and its beta is 0.42. Most recently the company’s share price was $3.04, and it changed around -$0.06 or -2.10% from the last close, which brings the market valuation of the company to $896.44M. ABCL at last check was trading at a discount to its 52-week high of $5.46, offering almost -79.61% off that amount. The share price’s 52-week low was $2.34, which indicates that the recent value has risen by an impressive 23.03% since then. We note from AbCellera Biologics Inc’s average daily trading volume that its 10-day average is 3.37 million shares, with the 3-month average coming to 3.18 million.
AbCellera Biologics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.22. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended ABCL as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. AbCellera Biologics Inc is expected to report earnings per share of -0.15 for the current quarter.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Instantly ABCL has been showing red trend so far today with a performance of -2.10% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.42 on recent trading dayincreased the stock’s daily price by 11.11%. The company’s shares are currently up 3.58% year-to-date, but still down -1.46% over the last five days. On the other hand, AbCellera Biologics Inc (NASDAQ:ABCL) is 0.17% up in the 30-day period. We can see from the shorts that 17.26 million shares have been sold at a short interest cover period of 5.37 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 39.2% from its current value. Analyst projections state that ABCL is forecast to be at a low of $5 and a high of $5.
AbCellera Biologics Inc (ABCL) estimates and forecasts
The year-over-year growth rate is expected to be -16.95%, down from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 7.58M in revenue for the current quarter. 2 analysts expect AbCellera Biologics Inc to make 13.97M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 9.2M and 9.95M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -17.62%. Forecasts for the next quarter put sales growth at 40.33%.
AbCellera Biologics Inc earnings are expected to increase by -15.13% in 2025, but the outlook is positive 1.59% per year for the next five years.
ABCL Dividends
AbCellera Biologics Inc’s next quarterly earnings report is expected to be released in March.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 23.07% of AbCellera Biologics Inc shares, and 39.38% of them are in the hands of institutional investors. The stock currently has a share float of 51.19%. AbCellera Biologics Inc stock is held by 199.0 institutions, with BAKER BROS. ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 9.4033% of the shares, which is about 27.53 million shares worth $81.48 million.
BAILLIE GIFFORD & CO, with 7.4852% or 21.91 million shares worth $64.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Biotechnology ETF and Vanguard Valley Forge Fds-Baillie Gifford Global Pos Impact Stock Fd were the top two Mutual Funds as of Nov 30, 2024. The former held 1.42 shares worth $4.29 million, making up 0.48% of all outstanding shares. On the other hand, Vanguard Valley Forge Fds-Baillie Gifford Global Pos Impact Stock Fd held roughly 454.44 shares worth around $1.38 million, which represents about 0.15% of the total shares outstanding.
